Epoetin beta

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes

Trial Timeline

Aug 6, 2014 → Apr 9, 2019

NCT ID

NCT02145026

About Epoetin beta

Epoetin beta is a approved stage product being developed by Roche for Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT02145026. Target conditions include Myelodysplastic Syndromes.

What happened to similar drugs?

6 of 18 similar drugs in Myelodysplastic Syndromes were approved

Approved (6) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

❌Placebo + Epoetin alfa + Placebo + Epoetin alfaJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02145026	Approved	Completed	Aug 6, 2014	Apr 9, 2019	Myelodysplastic Syndromes
NCT01809314	Pre-clinical	Completed	Mar 1, 2008	Oct 1, 2009	Anemia
NCT00776425	Approved	Completed	Jan 1, 2007	Nov 1, 2012	Anemia
NCT02608060	Approved	Terminated	Sep 1, 2006	Oct 1, 2007	Anemia
NCT02624141	Approved	Terminated	Apr 1, 2006	Dec 1, 2009	Anemia
NCT02827266	Phase 3	Completed	Oct 1, 2005	Jan 1, 2008	Anemia
NCT02564094	Approved	Completed	Feb 1, 2005	Jun 1, 2006	Anemia
NCT02569515	Approved	Completed	Oct 1, 2004	Jul 1, 2006	Anemia
NCT02554942	Approved	Completed	Jun 1, 2004	Sep 1, 2005	Anemia
NCT02761642	Phase 2	Completed	Feb 29, 2004	Mar 31, 2007	Anemia
NCT00354341	Phase 3	Completed	Sep 1, 2002	Jul 1, 2005	Anemia

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35